Shots:

• Under the existing collaboration agreement, Takeda has exercised an option to co-develop and co-commercialize DNL593 (PTV: PGRN) as brain-penetrant progranulin replacement therapy for the treatment of FTD-GRN
• In Jan 2018, Takeda entered into a collaboration agreement with Denali in which Takeda got an option for three programs including PTV: PGRN & obtains the right to develop and commercialize DNL593
• Denali receives an option fee and milestone upon achievement of clinical, regulatory & sales-based milestones. Both companies will share the development and commercialization costs and profits

to­Ref: Globenewswire | Image: Takeda